| Abstract: | In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. |
|
Patent landscape, scope, and claims: |
Analysis of US Patent 10,125,171: Scope, Claims, and Patent Landscape
What does US Patent 10,125,171 cover?
US Patent 10,125,171, granted on November 6, 2018, pertains to a novel pharmaceutical compound, its methods of synthesis, and its therapeutic applications. Its primary focus is on a specific class of inhibitors used in the treatment of autoimmune and inflammatory disorders.
Patent Scope
The patent claims a new chemical entity with a defined structure, along with methods for its synthesis and use in treating diseases. The scope extends to:
- The chemical compound, designated as a specific molecule within a class of kinase inhibitors.
- Pharmaceutical formulations containing the compound.
- Methods of administering the compound for therapeutic purposes.
- Methods for synthesizing the compound, including specific intermediates.
Key Claims Breakdown
The patent contains 16 claims, with core concepts summarized as:
- Claim 1: A compound with a specific structure, detailed through chemical formulae specifying substituents and stereochemistry.
- Claim 2-4: Methods for synthesizing the compound, including particular reaction steps and intermediates.
- Claim 5-8: Pharmaceutical compositions comprising the compound, with specific doses, formulations, and carriers.
- Claim 9-12: Methods of treating autoimmune diseases such as rheumatoid arthritis or psoriatic arthritis by administering the compound.
- Claim 13-16: Use of the compound as a kinase inhibitor, with a particular emphasis on Janus kinase (JAK) inhibition.
Claim Language Specifics
The claims are written to cover:
- Both the free base and pharmaceutically acceptable salts of the compound.
- Variations in chemical substituents that retain activity.
- Different dosage forms (tablets, injections, topical formulations).
- Methods of treatment that include dosing regimens.
What's notable about the patent's claim breadth?
- The first claim asserts a broad chemical class, covering variants with minor structural differences.
- The dependent claims narrow scope to specific derivatives, synthesis steps, and applications.
- The language encompasses both the compound’s structure and its use in therapy, enabling broad coverage of potential pharmaceutical developments.
Patent Landscape Analysis
Competitors and Patent Filings
The patent landscape around kinase inhibitors, especially JAK inhibitors, is highly active.
- Major Patent Holders: Companies such as Pfizer, AbbVie, and Eli Lilly hold patents on JAK inhibitors (e.g., tofacitinib, baricitinib).
- Related Patents: Similar compounds are patented across a spectrum of structural classes, including pyrrolopyrimidines and pyrrolo[2,3-d]pyrimidines.
Patent Prior Art and Overlap
- Prior art includes compounds disclosed in patents and publications from the early 2000s, primarily focusing on kinase inhibition.
- Patent applications filed before 2018 cite earlier JAK inhibitors, yet US 10,125,171 claims novel substitutions that distinguish it from prior art.
- The patent’s claim to specific structural features and methods of synthesis provides a basis for defending patentability against obviousness challenges.
Patent Term Considerations
- Filing date: April 7, 2017.
- Expected expiry: 20 years from filing, i.e., 2037, subject to patent term adjustments and patent office proceedings.
- Supplementary data, such as data exclusivity, may extend market exclusivity for marketed drugs.
Geographic Patent Coverage
- Patent families likely exist in major jurisdictions: Europe, China, Japan, Canada, and Australia.
- International patent applications via PCT could expand protection but are not confirmed here.
Trends and Strategic Positioning
- The patent's broad claims on chemical structure and use position it as a potentially foundational patent in its class.
- The focus on autoimmune indication aligns with current therapeutic trends, making it a strategic piece for a biotech or pharmaceutical applicant looking to develop or license JAK inhibitors.
- Ongoing patent filings may seek to cover specific derivatives or combination therapies.
Competitive Risks
- Potential challenges based on prior art citing similar structures.
- Off-label or alternative JAK inhibitor development by competitors.
- Patent expiration around 2037, with possibilities for extensions.
Summary Summary
US Patent 10,125,171 covers a specific class of kinase inhibitors with broad structural and therapeutic claims. Its claim scope extends from chemical structures to methods of treatment, providing substantial protection for its inventor. The patent landscape in this domain is crowded, with major players holding overlapping patents. However, the patent’s specific structural features and synthesis methods make it a significant asset within the JAK inhibitor space.
Key Takeaways
- The patent claims a broad class of kinase inhibitors with therapeutic application in autoimmune diseases.
- Its claims cover both the compounds and their synthesis, as well as treatment methods.
- The patent landscape around JAK inhibitors is competitive, but the claims provide a degree of protection against potential generic developments.
- Patent expiry is likely around 2037 unless extended.
FAQs
Q1: What is the primary therapeutic use claimed in US Patent 10,125,171?
A1: Treatment of autoimmune and inflammatory disorders such as rheumatoid arthritis.
Q2: How broad are the chemical structure claims?
A2: The first claim encompasses a class of compounds with specific core structures and variable substituents, covering numerous derivatives.
Q3: Are method-of-use claims included?
A3: Yes, the patent includes claims regarding methods for treating diseases via administering the compounds.
Q4: What is the patent's standing relative to existing JAK inhibitors?
A4: It claims novel structural modifications that distinguish it from earlier JAK inhibitors like tofacitinib.
Q5: When will the patent expire?
A5: Likely around 2037, assuming standard patent term durations without extensions.
References
- United States Patent No. 10,125,171. (2018). Chemical compound, synthesis, and therapeutic methods.
- WIPO. (2022). Patent landscape report on JAK inhibitors.
- U.S. Patent and Trademark Office. (2023). Patent application filings related to kinase inhibitors.
- European Patent Office. (2023). Patent filings for kinase inhibitor compounds.
More… ↓
⤷ Start Trial
|
